ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)

Data ReadoutpositiveantimiR-23bPositive

AI Analysis

Summary

ARTHEx Biotech published preclinical data showing its antimiR-23b candidate, delivered via the BOOST-ON platform, crosses the blood-brain barrier and improves behavioral outcomes in a DM1 model by correcting disease biology.

Outcome Details

Preclinical data demonstrate systemic delivery of antimiR-23b reaches the brain, corrects disease biology, and improves DM1-related behavioral alteration

Importance:5/10

Sentiment:

0.70

preclinicalCNSneurologyrare diseasemyotonic dystrophyantisense

Related Companies

$BNN.DE $TRAX

Read the original article

Published by PR Newswire Biotech on July 23, 2026 7:00 AM

Read Original